^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Inqovi (decitabine/cedazuridine) (DNMT inhibitor, Cytidine deaminase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
Excerpt:
6 of 8 DNMT3A-mutated patients (75%) achieved CR, compared with 13 of 38 patients with wild type DNMT3A (34%; P=0.05; Table 2). Notably, all five patients with mutated DNMT3A and mutated NPM1 achieved CR, a significantly better response rate than among the remaining patients with other genotypes (14/41 (34%); P=0.008).
Trial ID:
